Abstract
Only few studies have investigated pharmacologic treatment for juvenile PTSD. Antiadrenergic agents are an interesting option, because of an autonomic nervous system hyperactivation in PTSD. Prazosin, an α-1 antagonist, has proven its efficacy in an adult population. In the pediatric population, few data support its use for nightmares and sleep disturbances in PTSD. We aim to assess the efficacy and safety of prazosin in a pediatric population.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the American Academy of Child & Adolescent Psychiatry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
